7068 results for
Refine Your Search
A Polyomic Approach to Chronic Graft-versus-Host Disease (cGvHD) Biomarkers in Adults
Our team is the first to develop a polyomic pediatric cGvHD biomarker test for assessing the risk of developing cGvHD. A cooperative adult phase III c…
Marco Ruella
Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Ita…
A First-in-human Clinical Trial of CD5 knocked-out Chimeric Antigen T Cells for T-cell Lymphomas
This proposal seeks to develop for the first time in humans a novel CD5 knocked out (KO) anti-CD5 chimeric antigen receptor T cell (CART) product for …
Anti-Sox2 immunotherapy to prevent multiple myeloma relapse
Advances in multiple myeloma (MM) therapy have improved survival, but serial cycles of response and relapse still lead to treatment-refractory and fat…
Aileen Rowan
After completing a PhD in Immunology at Trinity College Dublin, I moved to Imperial College London to study how persistent infection with a virus caus…
Detection and treatment of Adult T cell leukemia/lymphoma in the premalignant stage.
Clonally expanded T cells carrying somatic mutations circulate in the premalignant phase of Adult T cell leukemia/lymphoma (ATL). We will develop capt…
Peter Klein
Peter Klein is a Professor of Medicine and Attending Physician in the Division of Hematology-Oncology at the Perelman School of Medicine at the Univer…
Targeting splicing factor mutant myelodysplastic syndromes through GSK-3
Myelodysplasia (MDS) is a lethal stem cell disorder characterized by defective blood formation and progression to leukemia. MDS is frequently caused b…
Precision Targeting of Hairy Cell Leukemia using Chimeric Antigen Receptor T cells
<p>Though effective treatments in hairy cell leukemia and variant (HCLv) exist, they are associated with profound immunosuppression; thus, more …
Lucas Ferrari De Andrade
Hello, I am Lucas Ferrari de Andrade and the principal investigator. I am from Brazil and with my wife we immigrated to the United States in 2014. We …
Optimizing MICA/B antibody for AML by selective binding to Fc activating receptors
Acute myeloid leukemia (AML) is a blood cancer characterized by poor clinical outcomes. We developed an antibody that inhibits AML in models by trigge…
Precision Medicine For DNMT3A-Mutant T-cell ALL
T-cell ALL is an aggressive blood cancer with poor overall survival, high relapse rates, and significant treatment-related side effects. Using primary…
Thomas Kipps
Thomas Kipps, MD, PhD, is Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Thera…
Targeting Oncoembryonic Antigens ROR1 and ROR2 For Therapy Of Patients With Hairy Cell Leukemia
We will study the function of ROR1 and ROR2 on HCL cells that we have collected from 120 patients, examining whether they influence expression of gene…
Frederike Kramer
My current research explores the mechanisms by which epigenetic mutations drive the progression of myeloproliferative neoplasms (MPN). Throughout my g…
Investigating the Role of ASXL1 Mutations in CALR-mutated Myeloproliferative Neoplasms
My research focuses on myeloproliferative neoplasms (MPN) and the mutations that drive the progression of these blood cancers. Currently, I am investi…
Defining PIK3R5-related PI3K gamma dependency as a novel therapeutic target in blood cancers including BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive blood cancer without adequate treatment. In a genome-wide CRISPR interference sc…
Qingyu Luo
Qingyu Luo is a research fellow in Dr. Andrew Lane’s lab at the Dana-Farber Cancer Institute and a research fellow at Harvard Medical School. He is fo…
Christopher Booth
I performed my undergraduate studies at the University of Cambridge, UK, graduating in 2012 with a BA and MSci in Natural Sciences (Biochemistry).
Mechanisms of Pathogenesis by MYB Fusions in Blastic Plasmacytoid Dendritic Cell Neoplasm
The transcription factor MYB has long been associated with leukemia, but how it contributes to disease is poorly understood. Fusions of MYB to other p…
Jeremy Baeten
I began my career at The Ohio State University, where I studied blood vessel development and received my PhD in the lab of Dr. Brenda Lilly. After gra…
Combined targeting of ATR and replicative stress in TP53-mutated AML
This research will test a promising new drug combination in acute myeloid leukemia (AML) carrying TP53 gene mutations, which is resistant to chemother…
Eugenio Morelli
Eugenio Morelli, MD, is an Instructor in Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Morelli's research interest is t…
Defining the Biologic and Therapeutic Significance of the Novel Long Noncoding RNA MYND in Multiple Myeloma
Long non-protein coding RNAs (lncRNAs) are fundamental for proper cell function, but their purpose is poorly understood in multiple myeloma. To system…
Caner Saygin
I am a physician scientist focusing on treating patients with leukemia, and studying leukemia biology and novel experimental therapeutics in research …